Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study

<h2>Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the safety of statins mainly atorvastatin on liver as estimated by...

Full description

Bibliographic Details
Main Authors: Ramin Talaie, Mohammad Bagher Motevallian
Format: Article
Language:English
Published: Shahid Beheshti University of Medical Sciences 2015-07-01
Series:Novelty in Biomedicine
Subjects:
Online Access:http://journals.sbmu.ac.ir/index.php/nbm/article/view/7657
id doaj-3fe9cd1b0f7049459142582a8c9eaae2
record_format Article
spelling doaj-3fe9cd1b0f7049459142582a8c9eaae22020-11-25T01:23:21ZengShahid Beheshti University of Medical SciencesNovelty in Biomedicine2345-33462345-39072015-07-0133991025361Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective StudyRamin Talaie0Mohammad Bagher Motevallian1Department of Internal Medicine, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Internal Medicine, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran<h2>Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the safety of statins mainly atorvastatin on liver as estimated by liver aminotransferase assay.</h2><p><strong>M</strong><strong>aterials and Methods: </strong>Patients with indication of atorvastatin were included the study. As a before and after study all the patients underwent serum level measurement of aminotransferases at the beginning and after three month of taking the drug.</p><p><strong>R</strong><strong>es</strong><strong>ults and Conclusion: </strong>HMG-COA reductase as atorvastatin should be safe in different doses 20,40 and 80 mg in patient with hyperlipidemia with and without cardiac disease without significant hepatotoxicity.</p>http://journals.sbmu.ac.ir/index.php/nbm/article/view/7657Keywords: HMGG-COA reductase, hepatotoxicity, statins, atorvastatin
collection DOAJ
language English
format Article
sources DOAJ
author Ramin Talaie
Mohammad Bagher Motevallian
spellingShingle Ramin Talaie
Mohammad Bagher Motevallian
Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
Novelty in Biomedicine
Keywords: HMGG-COA reductase, hepatotoxicity, statins, atorvastatin
author_facet Ramin Talaie
Mohammad Bagher Motevallian
author_sort Ramin Talaie
title Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
title_short Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
title_full Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
title_fullStr Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
title_full_unstemmed Evaluation of Atorvastatin Safety on Liver Function Tests, a Prospective Study
title_sort evaluation of atorvastatin safety on liver function tests, a prospective study
publisher Shahid Beheshti University of Medical Sciences
series Novelty in Biomedicine
issn 2345-3346
2345-3907
publishDate 2015-07-01
description <h2>Background: Although lipid lowering agents as statins are used frequently in hyperlipidemic patients as well as patients with cardiac disease, they could have major hepatic side effects, the aim of this study is to evaluate the safety of statins mainly atorvastatin on liver as estimated by liver aminotransferase assay.</h2><p><strong>M</strong><strong>aterials and Methods: </strong>Patients with indication of atorvastatin were included the study. As a before and after study all the patients underwent serum level measurement of aminotransferases at the beginning and after three month of taking the drug.</p><p><strong>R</strong><strong>es</strong><strong>ults and Conclusion: </strong>HMG-COA reductase as atorvastatin should be safe in different doses 20,40 and 80 mg in patient with hyperlipidemia with and without cardiac disease without significant hepatotoxicity.</p>
topic Keywords: HMGG-COA reductase, hepatotoxicity, statins, atorvastatin
url http://journals.sbmu.ac.ir/index.php/nbm/article/view/7657
work_keys_str_mv AT ramintalaie evaluationofatorvastatinsafetyonliverfunctiontestsaprospectivestudy
AT mohammadbaghermotevallian evaluationofatorvastatinsafetyonliverfunctiontestsaprospectivestudy
_version_ 1725122738116362240